Scalper1 News
Specialty drugmaker Shire faced a future as a stand-alone company Thursday after AbbVie directors late Wednesday voted against a planned acquisition. Investors and analysts seemed optimistic, though, as Shire (SHPG) stock was up 3% in early trading on the stock market today, near 175.50. Leerink analyst Jason Gerberry wrote in a research note Thursday that Shire is unlikely to attract another buyer at this point. Though Pfizer (PFE) and Allergan Scalper1 News
Scalper1 News